152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL.
Saved in:
| Title: | 152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL. |
|---|---|
| Authors: | Wu, Jia-Di1 (AUTHOR), Wang, Zhi-Qiang1 (AUTHOR), Zhao, Ze-Rui1 (AUTHOR), Li, Qiao-Qiao1 (AUTHOR), Li, Zhi-Chao1 (AUTHOR), Li, Yu-Hong1 (AUTHOR) |
| Source: | Diseases of the Esophagus. 2023 Supplement, Vol. 36, p1-1. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
